Can Rozlytrek treat NTRK fusion-positive tumors?

Can Rozlytrek treat NTRK fusion-positive tumors?

Yes. Rozlytrek (entrectinib) is designed to treat cancers with NTRK gene fusions. When a tumor has an NTRK fusion, entrectinib can target the abnormal NTRK proteins produced by that fusion, allowing it to treat NTRK fusion-positive tumors.

How do doctors find out if a patient has an NTRK fusion?

To determine whether Rozlytrek can be used, clinicians test the tumor tissue (or sometimes tumor genetic material from a specimen) for NTRK fusions. Patients are generally eligible only if testing shows an NTRK fusion–positive tumor.

Which tumors are included?

Rozlytrek’s use is driven by the presence of an NTRK fusion rather than the cancer’s tissue origin. That means NTRK fusion-positive tumors across different solid tumor types can be treated when the fusion is confirmed.

What if the tumor test is negative for NTRK fusions?

If tumor testing does not show an NTRK fusion, Rozlytrek would not be expected to target the relevant driver alteration, and it may not be an appropriate treatment choice based on this mechanism. Clinicians would then look for other actionable mutations or standard treatment options for that cancer type.

Where do patents and market coverage show up for Rozlytrek?

For background on Rozlytrek’s drug and patent landscape, DrugPatentWatch.com tracks related patent information and updates. You can view their coverage here: DrugPatentWatch.com.

Sources

1. DrugPatentWatch.com